Form 4: Apellis Pharmaceuticals Acquired by Biogen for $41/Share

Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.

Summary

• Apellis Pharmaceuticals, Inc. has completed its merger with a subsidiary of Biogen Inc.
• Shareholders received $41.00 per share in cash.
• Shareholders also received one non-transferable contingent value right (CVR) per share, offering up to $4.00 in additional potential payments based on future milestones.
• All outstanding equity awards, including RSUs and stock options, were converted into the right to receive the cash offer price and CVRs, subject to specific vesting and performance conditions.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides a definitive cash exit at a premium, with additional upside potential via CVRs.

Positives

• Shareholders received a definitive cash payment of $41.00 per share.
• The inclusion of a CVR provides potential upside of up to $4.00 per share if specific milestones are met.
• Equity holders received liquidity for their holdings through the merger process.

Negatives

• The company is no longer an independent publicly traded entity.
• The CVRs are non-transferable and contingent on future performance, meaning the full $4.00 value is not guaranteed.

Risks

• The realization of the $4.00 CVR value is subject to the achievement of specific, undisclosed milestones.
• Payments related to converted RSU awards remain subject to continued service requirements for employees.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Biogen; future operations will be integrated into the parent company's structure.

Management Comments

• The compensation committee certified that the Relative TSR as of May 8, 2026, was at the 93.3rd percentile, resulting in a 200% payout for specific performance-based RSUs.

Industry Context

StockSavvy.ai notes that this acquisition reflects ongoing consolidation in the biotechnology sector, where larger pharmaceutical firms like Biogen are acquiring specialized companies to bolster their pipelines.

Comparison to Industry Standards

• The use of CVRs is a standard mechanism in biotech M&A to bridge valuation gaps between buyers and sellers regarding clinical trial outcomes.
• The $41.00 cash offer represents a premium typical for mid-cap biotech acquisitions.

Stakeholder Impact

• Shareholders have been cashed out of their positions.
• Employees with outstanding equity awards are subject to the conversion terms of the merger agreement.

Next Steps

• Integration of Apellis Pharmaceuticals into Biogen operations.
• Monitoring of milestones related to the CVR agreement for potential future payouts.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Right, Tender Offer